CAMBRIDGE, Mass.– AIRNA, a biotech firm developing RNA editing therapeutics for rare and common conditions, has appointed Tamara Joseph as Chief Legal Officer and Kristina Storey as Senior Vice President, Head of Regulatory Affairs.
The company said the hires come as it advances its regulatory strategy for AIR-001, a potential treatment for alpha-1 antitrypsin deficiency.
“Having Tamara embedded in our leadership team will be instrumental as we work to create meaningful RNA editing therapies for patients,” said Kris Elverum, AIRNA’s president and CEO.
Joseph, who has nearly 30 years of experience in legal, compliance, and corporate governance in biotech and public health organizations, was most recently CLO at Spero Therapeutics. She has also held senior legal roles at Millendo Therapeutics, Enzyvant Therapeutics, InVivo Therapeutics, and Cubist Pharmaceuticals. She currently chairs the board of Genflow Biosciences.
Storey brings over 20 years of expertise in clinical development and regulatory strategy, having led regulatory affairs at Fulcrum Therapeutics, Pharvaris, and Momenta Pharmaceuticals. Her background includes overseeing global regulatory interactions and securing product approvals across multiple therapeutic areas.
Both executives will play key roles as AIRNA moves from preclinical development toward clinical trials and potential commercialization.
